Given Imaging (Nasdaq: GIVN; TASE: GIVN) said yesterday that the German Gemeinsame Bundesausschuss (Joint Federal Committee) will evaluate its capsule endoscopy for out-patient coverage under the German national insurance program which covers most of Germany's 82 million citizens. About 10% of German citizens currently have coverage for PillCam Small Bowel through private health insurers.
The Joint Federal Committee will obtain input from medical experts, scientific societies, professional associations and patient organizations and recommend coverage, if the result of the consultation is positive.
Given Imaging president and CEO Homi Shamir said, "We are pleased that the German public health system will evaluate PillCam SB, and anticipate a decision in the next 12 to 18 months. We also expect to receive a monetary code for reimbursement in France in the first half of 2008, as well as additional reimbursement polices for PillCam SB and PillCam Esophagus in the US and other countries this year."
Given Imaging's share closed up 2.9% at $16.45 on Nasdaq yesterday, giving the company a market of $480 million. The company's share was up 3% in morning trading on the Tel Aviv Stock Exchange (TASE).
Published by Globes [online], Israel business news - www.globes.co.il - on January 29, 2008
© Copyright of Globes Publisher Itonut (1983) Ltd. 2008